# 1 32943/KMO/A97

10

The state of the s

20

### WHAT IS CLAIMED IS:

- 5 1. A process for stabilizing a blood protein solution comprising:
  - (a) providing a blood protein solution;
  - (b) adding to the solution hydroxypropyl- $\alpha$ -cyclodextrin in an amount sufficient to form a stable complex with the protein; and
  - (c) lyophilizing the solution of step (b) to form a lyophilized protein/hydroxypropyl-α-cyclodextrin complex.
    - 2. The process according to claim 1, further comprising reconstituting the lyophilized protein/hydroxypropyl-α-cyclodextrin complex.
- 3. The process according to claim 1, further comprising heating the blood protein solution, before or after adding hydroxypropyl-α-cyclodextrin, at least about 60°C for a time sufficient to inactivate any viruses present in the protein/hydroxypropyl-α-cyclodextrin complex.
  - 4. The process according to claim 3 wherein the blood protein solution is heated for at least about 10 hours.
  - 5. The process according to claim 3 wherein the blood protein solution is heated to a temperature of at least about 80°C for at least about 72 hours.
- 6. The process according to claim 3 wherein the blood protein solution is heated to about 100°C for at least about 1 hour.
  - 7. The process according to claim 1, further comprising subjecting the blood protein solution, before or after adding the hydroxypropyl- $\alpha$ -cyclodextrin, to a solvent detergent viral inactivation step.
    - 8. The process according to claim 1, wherein the hydroxypropyl- $\alpha$ -cyclodextrin is present in the protein solution in an amount ranging from about 0.5% wt/vol. to about 15% wt/vol.

# 1 32943/KMO/A97

5

15

20

The first the first that the first two than the first that the

- 9. The process according to claim 1, wherein the hydroxypropyl- $\alpha$ -cyclodextrin is present in the protein solution in an amount ranging from about 1% wt/vol. to about 12% wt/vol.
- 10. The process according to claim 2, wherein the protein is present in the reconstituted protein/hydroxypropyl- $\alpha$ -cyclodextrin complex in an amount greater than about 0.1% wt/vol.
- 11. The process according to claim 2 wherein the protein is present in the reconstituted protein /hydroxypropyl-α-cyclodextrin complex in an amount from about 1% to about 8%.
  - 12. The process according to claim 1 wherein the protein is selected from the group consisting of albumin, Factor II, Factor VII, Factor VIII, Factor IX, Factors X and X<sub>a</sub>, fibrinogen, antithrombin III, transferrin, haptoglobin, gamma globulins, fibronectin, protein C, protein S, thrombin and C1-inhibitor.
    - 13. The process according to claim 1, wherein the protein is fibrinogen.
    - 14. The process according to claim 12, wherein the hydroxypropyl- $\alpha$ -cyclodextrin is present in the protein solution in an amount ranging from about 0.5% wt/vol. to about 15% wt/vol.
- 15. The process according to claim 12, wherein the hydroxypropyl-α-cyclodextrin is present in the protein solution in an amount ranging from about 2% wt/vol. to about 12% wt/vol.
  - 16. The process according to claim 12, wherein the fibrinogen is present in the reconstituted protein/hydroxypropyl-α-cyclodextrin complex in an amount greater than about 1% wt/vol.
  - 17. The process according to claim 12, wherein the protein is fibrinogen, and the fibrinogen is present in the reconstituted protein /hydroxypropyl- $\alpha$ -cyclodextrin complex in an amount from about 3% wt/vol. to about 10% wt/vol.

5

15

20

25

- 18. A process for stabilizing a fibrinogen solution comprising:
  - (a) providing a fibrinogen solution;
- (b) adding to the solution hydroxypropyl- $\alpha$ -cyclodextrin in an amount sufficient to form a stable complex with the protein;
- (c) lyophilizing the solution of step (b) to form a lyophilized fibrinogen/hydroxypropyl-α-cyclodextrin complex; and
- (d) reconstituting the lyophilized fibrinogen/hydroxypropyl-α-cyclodextrin complex.
  - 19. A lyophilized blood protein/hydroxypropyl-α-cyclodextrin complex prepared by:
    - (a) providing a blood protein solution;
  - (b) adding to the solution hydroxypropyl-α-cyclodextrin in an amount sufficient to form a stable complex with the protein; and
  - (c) lyophilizing the solution of step (b) to form the lyophilized blood protein/hydroxypropyl-α-cyclodextrin complex.
    - 20. A blood protein product prepared by:
      - (a) providing a blood protein solution;
  - (b) adding to the solution hydroxypropyl- $\alpha$ -cyclodextrin in an amount sufficient to form a stable complex with the protein;
  - (c) lyophilizing the solution of step (b) to form a lyophilized protein/hydroxypropyl- $\alpha$ -cyclodextrin complex; and
  - (d) reconstituting the lyophilized protein/hydroxypropyl-α-cyclodextrin complex.
    - 21. A fibrinogen product prepared by:
      - (a) providing a fibrinogen solution;
  - (b) adding to the solution hydroxypropyl-α-cyclodextrin in an amount sufficient to form a stable complex with the protein;
    - (c) lyophilizing the solution of step (b) to form a lyophilized fibrinogen/hydroxypropyl- $\alpha$ -cyclodextrin complex; and
- (d) reconstituting the lyophilized fibrinogen/hydroxypropyl-α-cyclodextrin complex.

# The state of the s

15

20

5

### 32943/KMO/A97

- 22. A blood protein product comprising a lyophilized solution of a stable complex of protein and hydroxypropyl-α-cyclodextrin.
- 23. The product according to claim 22, wherein the hydroxypropyl- $\alpha$ -cyclodextrin is present in the solution in an amount ranging from about 0.5% wt/vol. to about 15% wt/vol.
- 24. The product according to claim 22, wherein the hydroxypropyl-α-cyclodextrin is present in the solution in an amount ranging from about 1% wt/vol. to about 12% wt/vol.
  - 25. The product according to claim 22, wherein the blood protein is fibrinogen.
  - 26. A stabilized blood protein solution comprising a complex of the blood protein and hydroxypropyl-α-cyclodextrin.
  - 27. The solution according to claim 26, wherein the protein is present in the complex in an amount greater than about 3% wt/vol.
  - 28. The product according to claim 26, wherein the hydroxypropyl-α-cyclodextrin is present in the solution in an amount ranging from about 0.5% wt/vol. to about 15% wt/vol.
  - 29. The process according to claim 26, wherein the hydroxypropyl-α-cyclodextrin is present in the solution in an amount ranging from about 1% wt/vol. to about 12% wt/vol.
    - 30. The product according to claim 26, wherein the blood protein is fibrinogen.

30

25